 | | Vol. 10.13 – 19 April, 2024 |
| |
|
|
| Scientists developed a model to study the function of a fusion protein in the pathogenesis of diffuse gastric cancer (DGC). They evaluated its oncogenic activity and the biochemical effects of the fusion protein on the RHOA pathway and its downstream cell biological effects in the pathogenesis of DGC.
[Gut] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors observed reduced DEAH-box helicase 9 (DHX9) protein levels in IBD patients, and mice with conditional DHX9 depletion in the intestinal epithelium exhibited an increased susceptibility to experimental colitis.
[Nature Communications] |
|
|
|
| Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 2 (PREX2) emerged as an upregulated gene in radioresistant colorectal cancer (CRC) cells. It augmented the radioresistant capacity of CRC cells and demonstrated potential as a marker for predicting radioresistance efficacy.
[BMC Medicine] |
|
|
|
| Researchers provided evidence that bazedoxifene inhibited tumor growth via direct interaction with the gp130 receptor to suppress IL-6 and IL-11-mediated STAT3 signaling. Additionally, bazedoxifene combined with chemotherapy reduced cell proliferation and induced apoptosis in patient-derived organoids.
[Cell Death & Disease] |
|
|
|
| Researchers deciphered molecular pharmacological mechanisms and gene expression regulation for chymotrypsin signaling in intestinal epithelial cells.
[British Journal Of Pharmacology] |
|
|
|
| Scientists reported a sensitivity of the mRNA splicing machinery to phosphorylation changes in response to LB-100 in colorectal adenocarcinoma.
[EMBO Reports] |
|
|
|
|
| Investigators provide an overview of how intestinal organoids are being co-cultured with immune cells leading to substantial advances in their understanding of immune–epithelial interactions in the gut.
[Clinical & Experimental Immunology] |
|
|
|
|
| Palisade Bio, Inc. announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 inhibitor prodrug in development for patients affected by ulcerative colitis.
[Palisade Bio, Inc.] |
|
|
|
| With a new five-year, $1.84 million grant from the National Cancer Institute, researchers from Case Western Reserve University hope to take a step closer to developing new treatment options for people with metastatic colorectal cancer by studying how a protein involved in colorectal cancer growth functions.
[Case Western Reserve University] |
|
|
|
|
| May 29 – June 1, 2024
Vancouver, British Columbia, Canada |
|
|
|
|
|
|
| | Cold Spring Harbor Laboratory – Cold Spring Harbor, New York, United States |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | Monash University – Melbourne, Australia |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
